

Kelun Group, a 2015 Fortune 500 company in China, offers over 520 products and is the market leader of injectable and infusion technologies. Kelun Group's revenues in 2015 exceeded RMB 39 billion, or USD 6 billion. Currently, Kelun has 30,000+ employees in 90+ subsidiaries globally.

Kelun has R&D centers in Sichuan Chengdu, Tianjin, Suzhou and New Jersey (US). We are committed to R&D for small-molecule NCEs and biological NBEs, biosimilars, generic drugs, and new drug delivery systems (NDDS) in oncology, diabetes, hepatitis, cardiovascular and other major disease areas. Thomson Reuters in 2014 ranked Kelun the 4th most competitive pharm product pipeline in China.

Licensing needs: Small-Molecule, mAb, ADC, Bi-Specific Ab, Probody

Openings*: <https://kluspharmainc.gethired.com> 或 indeed.com 和 gethired.com search “Kelun” or “KLUS”

Please send your resume to hr@kluspharma.com

***总监职位 (Director level openings) :**

BD (新泽西, 波士顿, 圣地亚哥) (New Jersey, Boston, San Diego)

仿制药品种选择 Generics Portfolio Strategy (新泽西) (New Jersey)

生物药职位 (Biological openings) : 培养基开发 ^a(Cell Culture Development), 大规模细胞培养 (Large Scale Cell Line Development), 质量管理 (Quality Control), 生物药 cGMP 生产管理 (Biologicals cGMP Manufacturing), 大规模纯化 (Large Scale Purification), 质量分析/生物活性测定 (Analytical in Bioactivity)。

小分子创新和仿制 (Small Molecule openings) : 计算化学 (Computational Chemistry), DMPK, 药理 (Pharmacology), 毒理 (Toxicity), 合成工艺 (Synthesis Process Development)

制剂 ^a(Formulation), 分析 ^a(Analytical), 纳米粒 (Nanoparticle), 脂质体 (Liposome), 微球 (Microsphere)。

制剂 cGMP 生产管理 (cGMP Manufacturing Operation), cGMP 生产 QA (cGMP QA)

临床研究 (Clinical Research)

创新项目立项和靶点选择 (Innovative Drug Portfolio Strategy and Target Selection)

原料药合成和 DMF 报批 (API Synthesis Process Development & DMF Filing)

^a 中国/新泽西均有职位。其他为中国职位。